246 related articles for article (PubMed ID: 15975613)
1. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
2. Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice.
Sugawara M; Okamoto K; Kadowaki T; Kusano K; Fukamizu A; Yoshimura T
Drug Metab Dispos; 2010 Mar; 38(3):526-33. PubMed ID: 20007293
[TBL] [Abstract][Full Text] [Related]
3. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.
Wilkening S; Stahl F; Bader A
Drug Metab Dispos; 2003 Aug; 31(8):1035-42. PubMed ID: 12867492
[TBL] [Abstract][Full Text] [Related]
4. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Guillouzo A; Corlu A; Aninat C; Glaise D; Morel F; Guguen-Guillouzo C
Chem Biol Interact; 2007 May; 168(1):66-73. PubMed ID: 17241619
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: susceptibility markers.
Blum HE
IARC Sci Publ; 2001; 154():241-4. PubMed ID: 11220663
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism.
Lin J; Schyschka L; Mühl-Benninghaus R; Neumann J; Hao L; Nussler N; Dooley S; Liu L; Stöckle U; Nussler AK; Ehnert S
Arch Toxicol; 2012 Jan; 86(1):87-95. PubMed ID: 21735230
[TBL] [Abstract][Full Text] [Related]
7. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
Ozawa S
Rinsho Byori; 2003 Feb; 51(2):168-73. PubMed ID: 12690635
[TBL] [Abstract][Full Text] [Related]
8. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.
Le Vee M; Jigorel E; Glaise D; Gripon P; Guguen-Guillouzo C; Fardel O
Eur J Pharm Sci; 2006 May; 28(1-2):109-17. PubMed ID: 16488578
[TBL] [Abstract][Full Text] [Related]
9. Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.
Yoo HD; Lee YB
Arch Pharm Res; 2011 Nov; 34(11):1817-28. PubMed ID: 22139683
[TBL] [Abstract][Full Text] [Related]
10. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells.
Manov I; Bashenko Y; Hirsh M; Iancu TC
Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):213-24. PubMed ID: 16930294
[TBL] [Abstract][Full Text] [Related]
12. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans.
Chandrasekaran EV; Xue J; Neelamegham S; Matta KL
Carbohydr Res; 2006 Jun; 341(8):983-94. PubMed ID: 16545347
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
14. Aqueous extract from Spanish black radish (Raphanus sativus L. Var. niger) induces detoxification enzymes in the HepG2 human hepatoma cell line.
Hanlon PR; Webber DM; Barnes DM
J Agric Food Chem; 2007 Aug; 55(16):6439-46. PubMed ID: 17616135
[TBL] [Abstract][Full Text] [Related]
15. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues.
Myllynen P; Immonen E; Kummu M; Vähäkangas K
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1483-99. PubMed ID: 19785513
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
Johnson AD; Wang D; Sadee W
Pharmacol Ther; 2005 Apr; 106(1):19-38. PubMed ID: 15781120
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
18. Implications for therapy of drug-metabolizing enzymes in human colon cancer.
Mekhail-Ishak K; Hudson N; Tsao MS; Batist G
Cancer Res; 1989 Sep; 49(17):4866-9. PubMed ID: 2758417
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in drug-metabolizing enzymes and drug targets.
Hiratsuka M; Mizugaki M
Mol Genet Metab; 2001 Aug; 73(4):298-305. PubMed ID: 11509011
[No Abstract] [Full Text] [Related]
20. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
